KO

KOMIPHARM INTERNATIONAL CO., LTD.

Develops animal health products and novel drugs for human cancer and autoimmune diseases.

041960 | KO

Overview

Corporate Details

ISIN(s):
KR7041960006
LEI:
Country:
South Korea
Address:
경기도 시흥시 경제로 17, 시흥시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Komipharm International Co., Ltd. is a biopharmaceutical company with core operations in animal health and a strategic focus on human therapeutics. The company develops, manufactures, and sells a diverse portfolio of veterinary products, including vaccines, pharmaceuticals, and disinfectants for livestock, poultry, and companion animals. Leveraging over 50 years of industry experience, Komipharm is also engaged in the research and development of novel drugs for human use. Its pharmaceutical pipeline concentrates on creating therapeutic agents for challenging indications such as cancer pain and autoimmune diseases, as part of its strategy to expand into the global bio-industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(약식)
Korean 122.0 KB
2025-09-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 78.6 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-08-06 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-07-30 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 61.3 KB
2025-07-07 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.8 KB
2025-06-20 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 37.4 KB
2025-06-20 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 32.7 KB
2025-05-27 00:00
Capital/Financing Update
주요사항보고서(제3자의전환사채매수선택권행사)
Korean 23.3 KB
2025-05-14 00:00
Annual Report
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-29 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 14.4 KB
2025-04-23 00:00
Share Issue/Capital Change
전환청구권행사
Korean 11.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 31.6 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.1 KB
2025-03-26 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 32.7 KB

Automate Your Workflow. Get a real-time feed of all KOMIPHARM INTERNATIONAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOMIPHARM INTERNATIONAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOMIPHARM INTERNATIONAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ORASURE TECHNOLOGIES INC Logo
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America
OSUR
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden
ORX
ORGANIGRAM GLOBAL INC. Logo
Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.
United States of America
OGI
Organon & Co. Logo
A global healthcare company focused on women's health, biosimilars, and established brands worldwide.
United States of America
OGN
Oric Pharmaceuticals, Inc. Logo
Developing therapies to overcome resistance in lung and prostate cancer.
United States of America
ORIC
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland
ORNAV
Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America
ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.